Notice of Annual General Meeting of shareholders in CombiGene AB (publ)
Shareholders in CombiGene AB (publ) are hereby invited to attend the Annual
General Meeting at 2.30 p.m. on 3 May 2018 at Tellus, Medicon Village, Scheelevägen 2,
Lund. Registration for the meeting will commence one half-hour before the meeting
and will end when the meeting opens.
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.